Study Claims Ozempic Lowers Biological Age | PharmExec
Study Claims Ozempic Lowers Biological Age Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope in the fight against aging and related health issues.
The Turkish glees, language barrier
The Turkish Experience: A Language Barrier In traditional Botswana, a Setswana maxim states: “Go tsamaya ke go bona (the exper…
Community pharmacies and BioPharma: Advancing whole-patient care together
Community Pharmacies and BioPharma: Advancing Whole-Patient Care Together The healthcare landscape has become increasingly complex, with a…
Here’s why Utah’s Olympic organizers are in NYC this week
Utah's Olympic Organizers in NYC Leaders of Utah's 2034 Winter Games are in New York City to show support for American athletes competing …
Tin-top tales with Alain Menu
Tin-top tales with Alain Menu Destined to become a vet, Swiss driver Alain Menu decided to follow his heart and headed for the track. …
Older Patients and Women Bear the Brunt of CTD-ILD Burden
CTD-ILD Burden on Older Patients and Women The incidence and prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-…
OPPO, Ballet Philippines to promote Filipino Artistry with new partnership
OPPO and Ballet Philippines Partnership OPPO has announced a partnership with Ballet Philippines to promote Filipino artistry, coinciding …
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial Zenas BioPharma, Inc. announced positive results from the Phase 2 …
Government reveals environmental regulation reforms in effort to boost housebuilding
Government Reveals Environmental Regulation Reforms The government has announced changes to environmental regulations in an effort to boos…
Top 10 at 11: Healthcare and tech lead ASX lower as CSL and Wisetech bleed - Stockhead
ASX Market Update The Australian stock market is experiencing a decline, led by heavy falls in the healthcare and tech sectors, despite se…
Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
Kymera Therapeutics Presents New Preclinical Data for KT-579 Kymera Therapeutics, Inc. announced the presentation of new preclinical data …